Thigh vs. belly: can a simple injection switch ease pain and expand access?

NCT ID NCT07075510

Recruiting now Symptom relief Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times

Summary

This study looks at whether injecting daratumumab into the thigh is as safe and effective as the usual belly injection for people with plasma cell disorders like multiple myeloma. Daratumumab is an approved drug that helps the immune system kill abnormal plasma cells. The goal is to offer a less painful alternative injection site, making treatment easier for those who cannot tolerate belly injections. About 30 adults will take part at the University of Maryland.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States

Contact

Conditions

Explore the condition pages connected to this study.

PLASMA CELL DISORDER